Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test. Currently connected to more ...

Refusing to slow down since the start of the new year, shares of Tempus AI (NASDAQ: TEM) have skyrocketed nearly 99% since ...

Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health ...

Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation. The collaboration aims to develop and make ...

Tempus AI shares were up 14% ... instability status and companion diagnostic claims for colorectal cancer patients, said the Chicago-based company.

Regarding the transaction, the lawmaker disclosed on January 14 the accumulation of 50 call options in Tempus AI with a ...

Initially, Tempus AI's main initial focus has been on cancer research or oncology, where it has established business ties with roughly 2,500 institutions. According to its investor presentation ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Imagene's AI-based multigene panel for predicting non-small cell lung cancer biomarkers from biopsy images will be combined with Tempus' real-world data.

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.